Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ChemoCentryx, Inc. (NASDAQ: CCXI).

Full DD Report for CCXI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CCXI)

Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe PLC (NASDAQ:GSM), AXT Inc (NASDAQ:AXTI), ChemoCentryx, Inc. (N...
Source: GlobeNewswire
Date: August, 20 2018 08:20
ChemoCentryx 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by ChemoCentryx in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 10 2018 15:16
ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q2 2018 Results - Earnings Call Transcript
ChemoCentryx, Inc. (CCXI) Q2 2018 Results Earnings Conference Call August 09, 2018 05:00 PM ET Executives Steve Klass - VP, Burns McClellan Dr. Thomas Schall - President and CEO Susan Kanaya - EVP and Chief Financial and Administrative Officer Bill Fairey - COO Analysts K...
Source: SeekingAlpha
Date: August, 09 2018 23:36
ChemoCentryx beats by $0.01, beats on revenue
ChemoCentryx (NASDAQ: CCXI ): Q2 EPS of -$0.14 beats by $0.01 . More news on: ChemoCentryx, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:21
ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch o...
Source: GlobeNewswire
Date: August, 09 2018 16:05
ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018
MOUNTAIN VIEW, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018. ChemoCentryx executive management will host a conference cal...
Source: GlobeNewswire
Date: August, 02 2018 08:30
InflaRx: Buy The Dip
Shares of German biotech InflaRx ( IFRX ) have fallen by 10% since my initial reader inquiry article concluded that staying on the sidelines for a better entry point (due to lack of near term catalysts) was the right decision at that point in time. However, I emphatically stated that I ver...
Source: SeekingAlpha
Date: June, 29 2018 08:06
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
Institutional Top Ideas Series: Biotechnology Value Fund
In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo...
Source: SeekingAlpha
Date: June, 04 2018 09:19
Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mitel Networks Corporation (NASDAQ:MITL), Celestica, Inc. (NYSE:CLS), ...
Source: GlobeNewswire
Date: June, 04 2018 08:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0812.4010.7712.54710.733383,257
2018-05-1712.5012.4712.9011.8751463,017
2017-02-027.347.167.347.1082,211
2017-02-017.337.327.427.2776,922
2017-01-317.137.277.307.03147,187

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1311,24126,06543.1268Short
2018-12-124,53514,00332.3859Cover
2018-12-114,23726,64415.9023Cover
2018-12-104,06034,14111.8919Cover
2018-12-0752,47390,77057.8087Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CCXI.


About ChemoCentryx, Inc. (NASDAQ: CCXI)

Logo for ChemoCentryx, Inc. (NASDAQ: CCXI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CCXI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 06 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: CCXI)

      Daily Technical Chart for (NASDAQ: CCXI)


      Stay tuned for daily updates and more on (NASDAQ: CCXI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CCXI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CCXI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CCXI and does not buy, sell, or trade any shares of CCXI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/